Autologous vs allogeneic: why our chain of custody matters.

Autologous means cells taken from the patient receiving the therapy. Allogeneic means cells taken from someone else, typically an umbilical-cord donor, processed and stored for therapeutic use. Both are legitimate. They are not interchangeable, and the choice has consequences that begin in the lab and end in the consultation room.

The case for autologous

Autologous cells carry the patient's own immunological identity. There is no graft-versus-host risk, no compatibility testing, no anti-HLA workup. For a patient using cells now, where the underlying biology is intact, autologous is the cleaner clinical answer. It is also the model best suited to repeat dosing, the harvest, expansion and infusion cycle can run on a predictable cadence with the same biological material.

Most clients arriving for our stem-cell technology programme are running an autologous protocol, bone marrow or adipose harvest, in-house expansion, infusion within the same chain of custody. The cells leave the patient, are processed by the same laboratory team, and return to the same patient. No external lab. No transport between buildings. No box on a plane.

The case for allogeneic

Allogeneic, typically Wharton's-jelly-derived umbilical cord MSCs, has two real advantages: the donor cells are biologically younger, which matters when the patient's own progenitor pool is depleted, and the product can be produced in volume and quality-controlled at scale. For a forty-year-old with rheumatoid arthritis whose autologous yield is poor, allogeneic is often the better answer.

It is also the basis for newborn banking. The cells stored from your child's birth through our stem-cell banking programme are theirs first, and a sibling-allogeneic resource second. Both are legitimate use cases; both depend on how the cells were stored.

Why chain of custody is the load-bearing concept

The reason we run our own laboratory rather than outsource processing is not vertical-integration for its own sake. It is identity. Every cell product needs to be traceable to the patient who donated it, with no intermediate handling that could mix samples, lose paperwork, or introduce contamination outside the clinic's quality system. When the harvest, expansion and infusion all happen inside the same PIC/S-GMP environment, the chain of custody is one continuous line.

What that looks like in practice: bone-marrow or adipose harvest in the on-site operating room, immediate transfer to the cleanroom suite, ISCT-aligned characterisation of the cell product before expansion, in-process release testing during expansion, sterility and identity verification before release, and infusion in the same building. There is no courier. There is no second laboratory. This is one of the reasons our Bangkok flagship is structured the way it is.

What can go wrong without it

When stem-cell therapy is offered without that chain of custody, for example, a clinic that markets MSC infusions but outsources cell production to a third party, the patient is trusting that the box that arrived in the morning truly contains their own cells, characterised to the standard the consent form promised. That trust is sometimes warranted. It is not always warranted.

Why MSC products cannot be sold off-the-shelf like a tablet is covered in are stem cells available for retail purchase like other pharmaceuticals. The short version: living cells need a continuous quality environment, and that environment is the differentiator between a real regenerative practice and a brochure.

What this means for the conversation in clinic

When a new client sits down, the first question is rarely autologous-versus-allogeneic, it is what the underlying clinical objective is, and which biological substrate is best suited to it. We then walk the client through what the chain of custody will look like for the protocol we are proposing, including who handles the sample at each step, where it sits, and how it is verified. That conversation is what regenerative medicine should be.